{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:16:05Z","timestamp":1787224565462,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.09.012","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:04:09Z","timestamp":1758603849000},"page":"e120-e126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9982-7192","authenticated-orcid":false,"given":"Ryan","family":"Storgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Reingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-6895","authenticated-orcid":false,"given":"Rose","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-2479","authenticated-orcid":false,"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-3199","authenticated-orcid":false,"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.09.012_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"Spec Edition","key":"10.1016\/j.clml.2025.09.012_bib0002","first-page":"S1","article-title":"Toxicity of chimeric antigen receptor T cells and its management","volume":"4","author":"Wudhikarn","year":"2021","journal-title":"Blood Cell Ther"},{"key":"10.1016\/j.clml.2025.09.012_bib0003","unstructured":"University of Pennsylvania. CART19 to treat B-cell leukemia or lymphoma that are resistant or refractory to chemotherapy. ClinicalTrials.Gov 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT01029366. Accessed Jun 05, 2025."},{"key":"10.1016\/j.clml.2025.09.012_bib0004","unstructured":"Shah N. Anti-CD19 white blood cells for children and young adults with B cell leukemia or lymphoma. ClinicalTrials.Gov; 2020. https:\/\/www.clinicaltrials.gov\/study\/NCT01593696. Accessed Jun 05, 2025."},{"key":"10.1016\/j.clml.2025.09.012_bib0005","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.012_bib0006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy","volume":"75","author":"Rubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clml.2025.09.012_bib0007","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.09.012_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.012_bib0009","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamadermatol.2020.0636","article-title":"Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma","volume":"156","author":"Hu","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2025.09.012_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J Gene Med"},{"issue":"3","key":"10.1016\/j.clml.2025.09.012_bib0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2025.09.012_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1171031","article-title":"Case report: severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS","volume":"13","author":"Masucci","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.09.012_bib0013","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1111\/jdv.18892","article-title":"Cutaneous toxicity of CAR T-cell therapy: case report of a bullous life-threatening reaction","volume":"37","author":"Fiorillo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"32","key":"10.1016\/j.clml.2025.09.012_bib0014","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.09.012_bib0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.clml.2025.09.012_bib0016","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clml.2025.09.012_bib0017","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.012_bib0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.09.012_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:34:05Z","timestamp":1773182045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025042235"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}